Myriad Genetics Inc (MYGN) 10-K Annual Report August 2012

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 million and resulted in fiscal year 2012 revenue of $496.0 million, an increase of 23 percent over fiscal 2011. Fourth fiscal quarter diluted earnings per share were $0.34, an increase of 14 percent over the same period of the prior year. Fiscal 2012 diluted earnings per share equaled $1.30, an increase of 18 percent year-over-year.

“Myriad achieved record revenue and operating profits last year,” said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. “We are committed to building on this strong performance in fiscal 2013 as we continue to execute on our strategic directives: to grow existing tests and markets, to expand internationally and to launch new tests, including companion diagnostics, across a diverse set of major disease indications.”

Fourth Fiscal Quarter 2012 Results

•

Molecular diagnostic testing revenue in the fourth fiscal quarter equaled $127.5 million, an increase of 21 percent compared to the prior year period. Revenue from the Oncology segment equaled $87.0 million, an increase of 16 percent over the fourth fiscal quarter of 2011. Women’s Health revenue totaled $40.5 million, an increase of 32 percent over the same period in the prior year.

•

Revenue from the BRACAnalysis^® test, which represented 81.7 percent of total revenue in the fourth quarter, was $108.7 million, a 17 percent increase over the same period of the prior year.

•

Revenue from the COLARIS^® and COLARIS AP^® tests, which represented 8.7 percent of total revenue during the quarter, was $11.5 million, an increase of 51 percent compared to the same fiscal quarter of the prior year.

•

Myriad’s other molecular diagnostic tests contributed $7.3 million to fourth quarter revenue, or 5.5 percent of total revenue, an increase of 47 percent over the same period in the prior year.

•

Companion diagnostic service revenue in the fourth fiscal quarter equaled $5.5 million and represented 4.1 percent of total company revenue. Revenue in the fourth fiscal quarter of 2011 equaled $2.0 million as the Company acquired this business in May 2011.

The following information was filed by Myriad Genetics Inc (MYGN) on Tuesday, August 14, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899923/000119312512356879/d365488d10k.htm

View differences made from one year to another to evaluate Myriad Genetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Myriad Genetics Inc.

Continue

Assess how Myriad Genetics Inc's management team is paid from their Annual Proxy

Myriad Genetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Myriad Genetics Inc provided additional information to their SEC Filing as exhibits

Exhibit 21.1: List Of Subsidiaries Of The Registrant

Exhibit 23.1: Consent Of Independent Registered Public Accounting Firm

Exhibit 31.1: Section 302 Ceo Certification

Exhibit 31.2: Section 302 Cfo Certification

Exhibit 32: Section 906 Ceo And Cfo Certification

Ticker: MYGN
CIK: 899923
Form Type: 10-K Annual Report
Accession Number: 0001193125-12-356879
Submitted to the SEC: Wed Aug 15 2012 10:37:56 AM EST
Accepted by the SEC: Wed Aug 15 2012
Period: Saturday, June 30, 2012
Industry: In Vitro And In Vivo Diagnostic Substances

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/mygn/0001193125-12-356879.htm

Myriad Genetics Inc (MYGN) SEC Filing 10-K Annual report for the fiscal year ending Saturday, June 30, 2012

SEC Filings

MYGN Valuations

MYGN Annual Reports

MYGN Quarterly Reports

MYGN Corporate News